Compare JYNT & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYNT | ANIX |
|---|---|---|
| Founded | 2010 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.2M | 119.8M |
| IPO Year | 2014 | 2013 |
| Metric | JYNT | ANIX |
|---|---|---|
| Price | $8.42 | $3.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $17.00 | $8.67 |
| AVG Volume (30 Days) | 61.1K | ★ 209.9K |
| Earning Date | 05-07-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.93 | 12.82 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $117,696,356.00 | $210,000.00 |
| Revenue This Year | $12.23 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $60.07 | ★ N/A |
| Revenue Growth | ★ 15.49 | N/A |
| 52 Week Low | $7.50 | $2.32 |
| 52 Week High | $10.74 | $5.46 |
| Indicator | JYNT | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 58.73 |
| Support Level | $8.07 | $2.73 |
| Resistance Level | $9.49 | $3.89 |
| Average True Range (ATR) | 0.27 | 0.20 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 43.75 | 69.92 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.